What is the role of the bystander response in radionuclide therapies?

by Darren eBrady, Joe M O'Sullivan, Kevin M Prise
Published 2013-08-01

Exercise for advanced prostate cancer: a multicomponent, feasibility, trial protocol for men with metastatic castrate-resistant prostate cancer (EXACT)

by Malcolm Brown, Marie Murphy, Lauri McDermott, Helen McAneney, Joe M. O’Sullivan, Suneil Jain, Gillian Prue
Published 2019-08-01

DNA damage responses following exposure to modulated radiation fields.

by Colman Trainor, Karl T Butterworth, Conor K McGarry, Stephen J McMahon, Joe M O'Sullivan, Alan R Hounsell, Kevin M Prise
Published 2012-01-01

A kinetic-based model of radiation-induced intercellular signalling.

by Stephen J McMahon, Karl T Butterworth, Colman Trainor, Conor K McGarry, Joe M O'Sullivan, Giuseppe Schettino, Alan R Hounsell, Kevin M Prise
Published 2013-01-01

A novel CBCT-based method for derivation of CTV-PTV margins for prostate and pelvic lymph nodes treated with stereotactic ablative radiotherapy

by Ciara A. Lyons, Raymond B. King, Sarah O.S. Osman, Stephen J. McMahon, Joe M. O’Sullivan, Alan R. Hounsell, Suneil Jain, Conor K. McGarry
Published 2017-08-01

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

by Axel Heidenreich, Silke Gillessen, Daniel Heinrich, Daniel Keizman, Joe M. O’Sullivan, Joan Carles, Manfred Wirth, Kurt Miller, John Reeves, Monica Seger, Sten Nilsson, Fred Saad
Published 2019-01-01

Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis.

by Clare M McCourt, Darragh G McArt, Ken Mills, Mark A Catherwood, Perry Maxwell, David J Waugh, Peter Hamilton, Joe M O'Sullivan, Manuel Salto-Tellez
Published 2013-01-01

Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells

by Francesca Amoroso, Kimberley Glass, Reema Singh, Francisco Liberal, Rebecca E. Steele, Sarah Maguire, Rohinton Tarapore, Joshua E. Allen, Sandra Van Schaeybroeck, Karl T. Butterworth, Kevin Prise, Joe M. O’Sullivan, Suneil Jain, David J. Waugh, Ian G. Mills
Published 2021-02-01

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.

by Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, Hiu-Fung Yuen, Declan O'Rourke, Muhammad Babur, Brian A Telfer, Huw D Thomas, Patrick Keane, Thiagarajan Nambirajan, Chris Hagan, Joe M O'Sullivan, Chris Shaw, Kaye J Williams, Nicola J Curtin, David G Hirst, Tracy Robson
Published 2015-01-01